A First-in-Class platform for Targeted Protein Degradation of intrinsically disordered regions of proteins to balance protein homeostasis in oncology, neurology, innate and adaptive immune response, virology and ageing.
Presentation is available for download here.
At RDP Pharma, we are focused on getting our products into clinical trials and addressing the unmet medical needs of patients. The extensive experience of our team ensures that the right questions are asked, the right experiments conducted, and the right clinical studies implemented.
R&D Pipeline RDP Pharma AG 2025
For more information please click below.
FAQ – What you need to know
What is RDP Prompt (a RDP Pharma Company)?
PromptDegarder™ is wholly owned by RDP Pharma AG and will be spun off into a subsidiary.
How can I inquire more information about the PromptDegrader™ Platform?
Please, email info@rdp-pharma.com and a member of our business development team will respond shortly.
Who should I contact for investment inquiries?
Please, email info@rdp-pharma.com and a member of our business development team will respond shortly.